The role of mitochondrial energy metabolism in drug resistance and prognosis of lung adenocarcinoma: a multi-omics and machine learning strategy for predictive and personalized therapy.
Source check: Source checked. Not independent scientific confirmation.
Finding: Using single-cell RNA-sequencing and TCGA-LUAD data, the authors built a five-gene LASSO-Cox prognostic classifier, MDrisk, from mitochondrial-metabolism and drug-resistance features. Scores were associated with immune and tumor-genomic features and computationally inferred drug sensitivity; ALDOA silencing was followed by reduced lung-adenocarcinoma cell proliferation, migration and invasion in vitro. This does not show patient treatment benefit.
Technology: The MDrisk five-gene prognostic classifier was selected using LASSO-Cox and combinations of machine-learning algorithms applied to mitochondrial-metabolism and drug-resistance features.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- The MDrisk five-gene prognostic classifier was selected using LASSO-Cox and combinations of machine-learning algorithms applied to mitochondrial-metabolism and drug-resistance features.
- Test and result
- The primary article reports MDrisk development from single-cell RNA-sequencing and TCGA-LUAD data, assessment in training, internal-test and external GEO cohorts, associations with immune and tumor-genomic features, and computationally inferred drug sensitivity. In vitro ALDOA silencing experiments assessed lung-adenocarcinoma cell proliferation, migration and invasion. Drug sensitivity was computationally inferred; the study did not test whether MDrisk-guided therapy improves patient outcomes.
- Limitation / still unknown
- Drug sensitivity was computationally inferred, and cell experiments do not establish clinical treatment benefit or patient outcomes.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13472987/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.